Stay updated on Ensifentrine in COPD Patients: Safety & Efficacy Clinical Trial
Sign up to get notified when there's something new on the Ensifentrine in COPD Patients: Safety & Efficacy Clinical Trial page.

Latest updates to the Ensifentrine in COPD Patients: Safety & Efficacy Clinical Trial page
- Check6 days agoChange DetectedThe page now displays a new revision label (v3.5.4) replacing the previous v3.5.3, indicating an updated software release.SummaryDifference0.0%

- Check13 days agoChange DetectedThe sponsor designation in the study details was updated from Verona Pharma plc to Verona Pharma, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, signaling a change in the corporate structure and sponsor organization used for the trial.SummaryDifference0.1%

- Check20 days agoChange DetectedThe page now displays Revision: v3.5.3, replacing v3.5.2, indicating an updated page version rather than a substantive content change.SummaryDifference0.0%

- Check27 days agoChange DetectedNo changes were detected in the provided additions/deletions inputs.SummaryDifference0.0%

- Check34 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check41 days agoChange DetectedIQVIA Pty Ltd was added as a collaborator and Iqvia Pty Ltd was removed.SummaryDifference0.0%

Stay in the know with updates to Ensifentrine in COPD Patients: Safety & Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ensifentrine in COPD Patients: Safety & Efficacy Clinical Trial page.